Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor
Open Access
- 1 August 2000
- journal article
- research article
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 48 (8) , 1103-1110
- https://doi.org/10.1177/002215540004800807
Abstract
Epidermal growth factor receptor (EGFR), its variant, EGFRvIII, and tenascin are glioma-associated antigens that are hyperexpressed by neoplastic glial cells relative to normal brain, making them attractive antigenic targets for immunotherapy. Preliminary surveys indicate that oligodendroglial tumors also produce these proteins, although the exact patterns and degrees of reactivity are not known. In this study we examined the immunoreactivity of tenascin among 50 oligodendroglial tumors, including 25 well-differentiated oligodendrogliomas (WDOs) and 12 glioblastomas (GBMs) exhibiting high proportions of oligodendroglia-like cells. We used well-characterized immunoreagents with defined specificities against the target antigens on formalin-fixed, paraffin-embedded archival tissue. The tumors were graded according to WHO guidelines. Immunoreactivity was reported on a 1–3 scale according to staining intensity multiplied by a 1–3 distribution scale distribution within tumor as focal (1), multifocal (2), and diffuse (3) for both the parenchymal and the perivascular components. Although there is considerable overlap in antigen production among the grades of tumor, this study establishes the production of tenascin and wild-type EGFR (but not EGFR vIII) in oligodendroglial neoplasms and supports the concept that antigen production increases with tumor grade. (J Histochem Cytochem 48:1103–1110, 2000)Keywords
This publication has 26 references indexed in Scilit:
- Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic HybridizationThe American Journal of Pathology, 1999
- Treatment of oligodendroglioma: An updateNeuro-Oncology, 1999
- The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate speciesDifferentiation, 1997
- Tenascin-C Inhibits Oligodendrocyte Precursor Cell Migration by both Adhesion-Dependent and Adhesion-Independent MechanismsMolecular and Cellular Neuroscience, 1996
- Regulation of Oligodendrocyte Precursor Migration by Extracellular Matrix: Evidence for Substrate-Specific Inhibition of Migration by Tenascin-CDevelopmental Neuroscience, 1996
- The Extracellular Matrix Molecule Tenascin: Expression in the Developing Chick Retinotectal System and Substrate Properties for Retinal Ganglion Cell Neurites In vitroEuropean Journal of Neuroscience, 1995
- Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?)2-a preliminary reportJournal of Neuro-Oncology, 1995
- Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2International Journal of Cancer, 1992
- A six-armed oligomer isolated from cell surface fibronectin preparationsNature, 1984
- Oligodendrogliomas I. A clinical study of cerebral oligodendrogliomasCancer, 1980